You are here: Industry Insights > Alopecia areata

News List

Ritlecitinib improves scalp hair regrowth in alopecia trial europeanpharmaceuticalreview
August 06, 2021
Ritlecitinib was shown to reduce scalp hair loss to less than or equal to 20 percent after six months in Pfizer’s Phase IIb/III trial.
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata firstwordpharma
August 06, 2021
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating oral once-daily ritlecitinib in patients with alopecia areata, an autoimmune disease driven by an immune attack on the hair follicles.
Baricitinib enhances hair regrowth for alopecia areata patients europeanpharmaceuticalreview
April 22, 2021
New Phase III data shows once daily treatment with baricitinib significantly increases hair regrowth in adult patients with severe alopecia areata.
Concert Pharmaceuticals announces plans for CTP-543 phase 3 trials in alopecia areata pharmaceutical-business-review
April 06, 2020
Concert Pharmaceuticals announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.
Concert Pharmaceuticals Successfully Completes CTP-543 Open Label Trial americanpharmaceuticalreview
December 24, 2019
Concert Pharmaceuticals has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata.
Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata pharmafocusasia
March 07, 2019
Concert Pharmaceuticals, Inc. today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
Concert Pharmaceuticals initiates CTP-543 Phase II trial in alopecia areata cphi-online
May 05, 2017
Trial designed to evaluate the safety and efficacy of CTP-543 after 12 months of dosing with the primary efficacy analysis at week 24.